Keyphrases
Multiple Myeloma
100%
Acupuncture
100%
Painful Neuropathy
100%
Neuropathy
75%
Adverse Effects
50%
Bortezomib
50%
Thalidomide
50%
Clinical Trials
25%
Therapeutic Agents
25%
Treatment Options
25%
Serious Adverse Events
25%
AIDS/HIV
25%
Diabetic
25%
Adjunctive Therapy
25%
Treatment Duration
25%
Peripheral Neuropathy
25%
Dose Intensity
25%
Cumulative Dose
25%
Strong Potential
25%
Adequate Sample Size
25%
Sensory Neuropathy
25%
Allodynia
25%
Sleep Problems
25%
Analgesic Drugs
25%
Toxic Neuropathy
25%
Mood Problems
25%
Difficult to Manage
25%
Therapy Intensity
25%
Spontaneous Pain
25%
Chemotherapy-induced Neuropathic Pain
25%
Reduced Physical Activity
25%
Hyperpathia
25%
Limit Dose
25%
Length of Therapy
25%
Peripheral Neuropathic Pain
25%
Medicine and Dentistry
Multiple Myeloma
100%
Neuropathy
100%
Acupuncture
100%
Adverse Effect
28%
Bortezomib
28%
Treatment Duration
28%
Neuropathic Pain
28%
Thalidomide
28%
Clinical Trial
14%
Adverse Event
14%
Adjuvant Therapy
14%
Human immunodeficiency virus
14%
Diabetes Mellitus
14%
Sensory Neuropathy
14%
Physical Activity
14%
Hyperpathia
14%
Anodyne
14%
Allodynia
14%
Treatment Option
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Neuropathy
100%
Bortezomib
28%
Thalidomide
28%
Neuropathic Pain
28%
Clinical Trial
14%
Adverse Event
14%
Chemotherapy
14%
HIV
14%
Diabetes Mellitus
14%
Analgesic Agent
14%
Hyperalgesia
14%
Sensory Neuropathy
14%
Dose Limit
14%
Allodynia
14%
Immunology and Microbiology
Multiple Myeloma
100%
Thalidomide
100%
Human immunodeficiency virus
50%
Sample Size
50%
Physical Activity
50%
Hyperalgesia
50%
Neuroscience
Neuropathy
100%
Adverse Effect
25%
Neuropathic Pain
25%
Bortezomib
25%
Thalidomide
25%
Diabetes Mellitus
12%
Human immunodeficiency virus
12%
Adjuvant Therapy
12%
Hyperalgesia
12%
Allodynia
12%